ArticleNPJ precision oncology2025
Detection of cytogenetically cryptic PML-RARA fusion in acute promyelocytic leukemia by rapid next generation sequencing.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- The Diagnostic Evolution of Haematological Neoplasms: A Narrative Review of the Road to Two Genetically Focused Classification Systems Through a Resource-Limited Perspective.Diagnostics (Basel, Switzerland) · 2026Review
- Case report:Frontiers in oncology · 2026Article
- Acute Promyelocytic Leukemia: Pathophysiology, Diagnosis and Clinical Management.Hematology reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute promyelocytic leukemia (APL) is a medical emergency that requires treatment to be initiated as soon as the disease is suspected in order to decrease the risk of early death, which is mostly caused by APL-associated coagulopathy. Currently, the diagnosis of APL relies on the detection of PML-RARA fusion by fluorescence in situ hybridization (FISH). However, rare cases are cytogenetically cryptic, negative by FISH, and require other molecular techniques to detect the fusion. Moreover, next generation sequencing (NGS) has not been incorporated in the routine diagnosis of leukemia-associated fusions. Hereby, we present a clinical APL case, reported negative by FISH, where PML-RARA fusion was detected by next generation sequencing (NGS) within 48 h, indicating the benefit of incorporating rapid NGS into the routine diagnostic management of acute leukemia patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.